Literature DB >> 34290406

Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma.

Giacomo Oliveira1,2, Kari Stromhaug1, Susan Klaeger3, Tomasz Kula4,5, Dennie T Frederick6, Phuong M Le7, Juliet Forman7, Teddy Huang7, Shuqiang Li3,7, Wandi Zhang1, Qikai Xu4, Nicoletta Cieri1, Karl R Clauser3, Sachet A Shukla3,7, Donna Neuberg8, Sune Justesen9, Gavin MacBeath4, Steven A Carr3, Edward F Fritsch1,3, Nir Hacohen2,3,6, Moshe Sade-Feldman3,6, Kenneth J Livak1,7, Genevieve M Boland2,3,6, Patrick A Ott1,2,3,10, Derin B Keskin1,7, Catherine J Wu11,12,13,14.   

Abstract

Interactions between T cell receptors (TCRs) and their cognate tumour antigens are central to antitumour immune responses1-3; however, the relationship between phenotypic characteristics and TCR properties is not well elucidated. Here we show, by linking the antigenic specificity of TCRs and the cellular phenotype of melanoma-infiltrating lymphocytes at single-cell resolution, that tumour specificity shapes the expression state of intratumoural CD8+ T cells. Non-tumour-reactive T cells were enriched for viral specificities and exhibited a non-exhausted memory phenotype, whereas melanoma-reactive lymphocytes predominantly displayed an exhausted state that encompassed diverse levels of differentiation but rarely acquired memory properties. These exhausted phenotypes were observed both among clonotypes specific for public overexpressed melanoma antigens (shared across different tumours) or personal neoantigens (specific for each tumour). The recognition of such tumour antigens was provided by TCRs with avidities inversely related to the abundance of cognate targets in melanoma cells and proportional to the binding affinity of peptide-human leukocyte antigen (HLA) complexes. The persistence of TCR clonotypes in peripheral blood was negatively affected by the level of intratumoural exhaustion, and increased in patients with a poor response to immune checkpoint blockade, consistent with chronic stimulation mediated by residual tumour antigens. By revealing how the quality and quantity of tumour antigens drive the features of T cell responses within the tumour microenvironment, we gain insights into the properties of the anti-melanoma TCR repertoire.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34290406      PMCID: PMC9187974          DOI: 10.1038/s41586-021-03704-y

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   69.504


  37 in total

Review 1.  Adoptive T cell therapy: Boosting the immune system to fight cancer.

Authors:  Ernesto Leon; Raghuveer Ranganathan; Barbara Savoldo
Journal:  Semin Immunol       Date:  2020-11-29       Impact factor: 11.130

Review 2.  Towards personalized, tumour-specific, therapeutic vaccines for cancer.

Authors:  Zhuting Hu; Patrick A Ott; Catherine J Wu
Journal:  Nat Rev Immunol       Date:  2017-12-11       Impact factor: 53.106

3.  Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.

Authors:  Brian C Miller; Debattama R Sen; Rose Al Abosy; Kevin Bi; Yamini V Virkud; Martin W LaFleur; Kathleen B Yates; Ana Lako; Kristen Felt; Girish S Naik; Michael Manos; Evisa Gjini; Juhi R Kuchroo; Jeffrey J Ishizuka; Jenna L Collier; Gabriel K Griffin; Seth Maleri; Dawn E Comstock; Sarah A Weiss; Flavian D Brown; Arpit Panda; Margaret D Zimmer; Robert T Manguso; F Stephen Hodi; Scott J Rodig; Arlene H Sharpe; W Nicholas Haining
Journal:  Nat Immunol       Date:  2019-02-18       Impact factor: 25.606

4.  Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.

Authors:  Imran Siddiqui; Karin Schaeuble; Vijaykumar Chennupati; Silvia A Fuertes Marraco; Sandra Calderon-Copete; Daniela Pais Ferreira; Santiago J Carmona; Leonardo Scarpellino; David Gfeller; Sylvain Pradervand; Sanjiv A Luther; Daniel E Speiser; Werner Held
Journal:  Immunity       Date:  2019-01-08       Impact factor: 31.745

5.  Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8+ T Cells in Head and Neck Cancer.

Authors:  Sri Krishna; Peaches Ulrich; Eric Wilson; Falguni Parikh; Pooja Narang; Shanshan Yang; Amelia K Read; Seunghee Kim-Schulze; Jin G Park; Marshall Posner; Melissa A Wilson Sayres; Andrew Sikora; Karen S Anderson
Journal:  Cancer Res       Date:  2018-08-28       Impact factor: 12.701

6.  Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.

Authors:  Yannick Simoni; Etienne Becht; Michael Fehlings; Chiew Yee Loh; Si-Lin Koo; Karen Wei Weng Teng; Joe Poh Sheng Yeong; Rahul Nahar; Tong Zhang; Hassen Kared; Kaibo Duan; Nicholas Ang; Michael Poidinger; Yin Yeng Lee; Anis Larbi; Alexis J Khng; Emile Tan; Cherylin Fu; Ronnie Mathew; Melissa Teo; Wan Teck Lim; Chee Keong Toh; Boon-Hean Ong; Tina Koh; Axel M Hillmer; Angela Takano; Tony Kiat Hon Lim; Eng Huat Tan; Weiwei Zhai; Daniel S W Tan; Iain Beehuat Tan; Evan W Newell
Journal:  Nature       Date:  2018-05-16       Impact factor: 49.962

7.  An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.

Authors:  Caroline S Jansen; Nataliya Prokhnevska; Viraj A Master; Martin G Sanda; Jennifer W Carlisle; Mehmet Asim Bilen; Maria Cardenas; Scott Wilkinson; Ross Lake; Adam G Sowalsky; Rajesh M Valanparambil; William H Hudson; Donald McGuire; Kevin Melnick; Amir I Khan; Kyu Kim; Yun Min Chang; Alice Kim; Christopher P Filson; Mehrdad Alemozaffar; Adeboye O Osunkoya; Patrick Mullane; Carla Ellis; Rama Akondy; Se Jin Im; Alice O Kamphorst; Adriana Reyes; Yuan Liu; Haydn Kissick
Journal:  Nature       Date:  2019-12-11       Impact factor: 49.962

8.  PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.

Authors:  Alena Gros; Paul F Robbins; Xin Yao; Yong F Li; Simon Turcotte; Eric Tran; John R Wunderlich; Arnold Mixon; Shawn Farid; Mark E Dudley; Ken-Ichi Hanada; Jorge R Almeida; Sam Darko; Daniel C Douek; James C Yang; Steven A Rosenberg
Journal:  J Clin Invest       Date:  2014-03-25       Impact factor: 14.808

9.  Clonal replacement of tumor-specific T cells following PD-1 blockade.

Authors:  Kathryn E Yost; Ansuman T Satpathy; Daniel K Wells; Yanyan Qi; Chunlin Wang; Robin Kageyama; Katherine L McNamara; Jeffrey M Granja; Kavita Y Sarin; Ryanne A Brown; Rohit K Gupta; Christina Curtis; Samantha L Bucktrout; Mark M Davis; Anne Lynn S Chang; Howard Y Chang
Journal:  Nat Med       Date:  2019-07-29       Impact factor: 53.440

10.  Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

Authors:  Y Kawakami; S Eliyahu; K Sakaguchi; P F Robbins; L Rivoltini; J R Yannelli; E Appella; S A Rosenberg
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  52 in total

1.  Landscape of helper and regulatory antitumour CD4+ T cells in melanoma.

Authors:  Giacomo Oliveira; Kari Stromhaug; Nicoletta Cieri; J Bryan Iorgulescu; Susan Klaeger; Jacquelyn O Wolff; Suzanna Rachimi; Vipheaviny Chea; Kate Krause; Samuel S Freeman; Wandi Zhang; Shuqiang Li; David A Braun; Donna Neuberg; Steven A Carr; Kenneth J Livak; Dennie T Frederick; Edward F Fritsch; Megan Wind-Rotolo; Nir Hacohen; Moshe Sade-Feldman; Charles H Yoon; Derin B Keskin; Patrick A Ott; Scott J Rodig; Genevieve M Boland; Catherine J Wu
Journal:  Nature       Date:  2022-05-04       Impact factor: 49.962

Review 2.  TCR-sequencing in cancer and autoimmunity: barcodes and beyond.

Authors:  Kristen E Pauken; Kaitlyn A Lagattuta; Benjamin Y Lu; Liliana E Lucca; Adil I Daud; David A Hafler; Harriet M Kluger; Soumya Raychaudhuri; Arlene H Sharpe
Journal:  Trends Immunol       Date:  2022-01-25       Impact factor: 16.687

3.  Discovering dominant tumor immune archetypes in a pan-cancer census.

Authors:  Alexis J Combes; Bushra Samad; Jessica Tsui; Nayvin W Chew; Peter Yan; Gabriella C Reeder; Divyashree Kushnoor; Alan Shen; Brittany Davidson; Andrea J Barczak; Michael Adkisson; Austin Edwards; Mohammad Naser; Kevin C Barry; Tristan Courau; Taymour Hammoudi; Rafael J Argüello; Arjun Arkal Rao; Adam B Olshen; Cathy Cai; Jenny Zhan; Katelyn C Davis; Robin K Kelley; Jocelyn S Chapman; Chloe E Atreya; Amar Patel; Adil I Daud; Patrick Ha; Aaron A Diaz; Johannes R Kratz; Eric A Collisson; Gabriela K Fragiadakis; David J Erle; Alexandre Boissonnas; Saurabh Asthana; Vincent Chan; Matthew F Krummel
Journal:  Cell       Date:  2021-12-27       Impact factor: 41.582

Review 4.  Signal pathways of melanoma and targeted therapy.

Authors:  Weinan Guo; Huina Wang; Chunying Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

Review 5.  Archetypes of checkpoint-responsive immunity.

Authors:  Kwok Im; Alexis J Combes; Matthew H Spitzer; Ansuman T Satpathy; Matthew F Krummel
Journal:  Trends Immunol       Date:  2021-10-09       Impact factor: 16.687

6.  Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy.

Authors:  Adrienne M Luoma; Shengbao Suo; Yifan Wang; Lauren Gunasti; Caroline B M Porter; Nancy Nabilsi; Jenny Tadros; Andrew P Ferretti; Sida Liao; Cagan Gurer; Yu-Hui Chen; Shana Criscitiello; Cora A Ricker; Danielle Dionne; Orit Rozenblatt-Rosen; Ravindra Uppaluri; Robert I Haddad; Orr Ashenberg; Aviv Regev; Eliezer M Van Allen; Gavin MacBeath; Jonathan D Schoenfeld; Kai W Wucherpfennig
Journal:  Cell       Date:  2022-07-07       Impact factor: 66.850

Review 7.  Cancer vaccines: Building a bridge over troubled waters.

Authors:  MacLean C Sellars; Catherine J Wu; Edward F Fritsch
Journal:  Cell       Date:  2022-07-13       Impact factor: 66.850

Review 8.  CD8 T-cell heterogeneity during T-cell exhaustion and PD-1-targeted immunotherapy.

Authors:  Satomi Ando; Koichi Araki
Journal:  Int Immunol       Date:  2022-10-05       Impact factor: 5.071

Review 9.  Cancer vaccines: the next immunotherapy frontier.

Authors:  Matthew J Lin; Judit Svensson-Arvelund; Gabrielle S Lubitz; Aurélien Marabelle; Ignacio Melero; Brian D Brown; Joshua D Brody
Journal:  Nat Cancer       Date:  2022-08-23

10.  Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers.

Authors:  Frank J Lowery; Sri Krishna; Rami Yossef; Neilesh B Parikh; Praveen D Chatani; Nikolaos Zacharakis; Maria R Parkhurst; Noam Levin; Sivasish Sindiri; Abraham Sachs; Kyle J Hitscherich; Zhiya Yu; Nolan R Vale; Yong-Chen Lu; Zhili Zheng; Li Jia; Jared J Gartner; Victoria K Hill; Amy R Copeland; Shirley K Nah; Robert V Masi; Billel Gasmi; Scott Kivitz; Biman C Paria; Maria Florentin; Sanghyun P Kim; Ken-Ichi Hanada; Yong F Li; Lien T Ngo; Satyajit Ray; Mackenzie L Shindorf; Shoshana T Levi; Ryan Shepherd; Chris Toy; Anup Y Parikh; Todd D Prickett; Michael C Kelly; Rachel Beyer; Stephanie L Goff; James C Yang; Paul F Robbins; Steven A Rosenberg
Journal:  Science       Date:  2022-02-03       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.